Omega-7 (Palmitoleic Acid)

Supplements · §534

Eyes that feel grittier by the afternoon. A cholesterol number creeping the wrong way. A patch of dry skin that won't quit. These are the spots where omega-7 — a single fatty acid sold under names like Provinal or sea buckthorn oil — has a small but real case, anchored by one clean thirty-day trial that dropped inflammation markers by nearly half. The much louder marketing case ("lowers diabetes risk 60%") is built on observational data about a chemically different version of the molecule found in dairy fat, not the capsule on the shelf.

Do · Daily Evidence Mixed Chapter Supplements

One small clean trial does the heavy lifting: a month of capsules dropped inflammation markers nearly in half and nudged cholesterol the right way. The dry-eye benefit is the other reasonably-evidenced use. The bolder claims — diabetes prevention, longevity, daily energy — don't survive a careful read of the actual studies. About $25 a month, one capsule with food, fair to try if you have a specific reason and unfair to expect much from if you don't.

Palmitoleic acid is one specific fat — sixteen carbons long, with a single bend in the chain. Your liver makes some of it from the saturated fat you eat. The supplement version comes from either purified fish oil (concentrated down to almost-pure palmitoleate, sold under names like Provinal) or sea buckthorn berry pulp.

What makes it interesting is that, in modest amounts, it appears to behave less like fuel and more like a signal — travelling from fat tissue to other organs carrying a "tone down inflammation, improve how the cells handle sugar" message. Researchers gave this kind of fatty acid the name lipokine: a fat with hormonal duties.

Two things to hold onto. First, this is not omega-3. The numbering describes where the first bend in the chain sits, not what the molecule does. Omega-3 is the substrate for an entire family of inflammation-resolving molecules with a huge body of trial evidence behind it; omega-7 works through a narrower set of receptors and a much smaller body of trial evidence. Taking one is not a substitute for the other.

Second — and this is the weird part — the same molecule made inside your body doesn't always do the same thing as the same molecule in a capsule. When the liver overproduces palmitoleate because of too many carbs, that high blood level becomes a marker of fatty liver, not a fix for it. The supplement appears to bypass that pathway and end up distributed across tissues differently. The discrepancy is real and unsettled in the field (Frigolet 2017); it is one reason "we should all eat more dairy fat for the trans-palmitoleate" doesn't cleanly translate into a capsule recommendation.

What the trial actually showed

The single best human trial of supplemental omega-7 is small but clean. Sixty adults with elevated cholesterol, given either 220 mg of purified palmitoleate or an indistinguishable placebo, for thirty days. The endpoints were exactly what they should have been: a sensitive inflammation marker (high-sensitivity C-reactive protein, the same blood test cardiologists use to flag low-grade vascular inflammation) and a standard lipid panel. The results were clear enough to take seriously.

A smaller Japanese trial a few years later gave a similar dose for twelve weeks and saw the same directional improvements at smaller magnitudes (Yagi 2017). That's roughly it for the metabolic case in humans — one well-designed small trial, one underpowered confirmation, no large multi-site replication.

The dry-eye evidence is a separate and quieter case. Eighty-six dry-eye sufferers were randomised to sea buckthorn oil (delivering roughly the same palmitoleate dose) or placebo for three months; the active arm showed less of a rise in tear-film osmolarity — an objective measure of eye-surface stress — and reported fewer symptoms (Larmo 2010). Smaller trials have shown modest improvements in atopic dermatitis (Yang 1999) and post-menopausal vaginal dryness (Larmo 2014). The pattern: where the substance is acting on a barrier-lipid surface — the oil layer of the tear film, the skin barrier, the vaginal mucosa — there's a real but small signal.

And the famous "omega-7 lowers diabetes risk 60%" headline? That comes from two large observational studies of trans-palmitoleate — the slightly different version of the molecule found in dairy fat — where people with higher blood levels developed type-2 diabetes about half as often as people with lower levels (Mozaffarian 2010; Mozaffarian 2013). The finding is real. Two problems for the supplement story. Trans-palmitoleate is a different molecule from the cis-palmitoleate in capsules, with different receptor behaviour; and biomarker-correlation is not treatment effect — people whose blood carries more dairy fat differ in many other ways from people whose blood doesn't. Treating that headline as evidence for the supplement is the most common error in the category.

What most product pages get wrong

Three claims to be skeptical of when shopping.

"Omega-7 lowers diabetes risk by 60%." True about trans-palmitoleate as a dairy biomarker; not a defensible claim for the cis-palmitoleate inside a supplement capsule (see the evidence section above).
"Sea buckthorn oil is sea buckthorn oil." The plant produces two very different oils. The pulp oil from the berry is roughly a third palmitoleate. The seed oil from inside the berry has barely any — most of its fatty-acid content is linoleic and α-linolenic acid, more like a small omega-6/omega-3 mix. Labels often don't specify, and capsules can vary by a factor of ten in actual omega-7 content.
"It works like omega-3, just a different one." The omega-3 / omega-7 numbering is describing where the first chemical bond sits in the chain, nothing more. They have different jobs, different receptors, and the omega-3 evidence base is dozens of trials larger. Omega-7 is not a substitute and not a competitor.

Who actually has a reason to try it

From what the trials cover, four situations have a real (if small) case.

Mild dyslipidemia with elevated CRP. The Bernstein-trial population — borderline cholesterol numbers and a CRP above ~2 mg/L. Defensible as a low-cost addition to whatever else you're doing (diet, exercise, a statin if one's prescribed).
Evaporative dry eye, especially after menopause. Palmitoleate is part of the oil layer of the tear film, so the mechanism fits the symptom; the dry-eye trial showed a real signal. Often paired with omega-3 fish oil, which has its own (mixed) dry-eye literature.
Atopic dermatitis with stubborn dry skin. Modest trial evidence. The skin-barrier-lipid story is plausible, but topical emollients still come first; this is an adjunct.
Post-menopausal vaginal dryness. Small trial signal; worth a conversation with a clinician about how it fits alongside local estrogen, which has stronger evidence.

Less plausible: anyone hoping for cognitive sharpening, more daily energy, or weight loss. There is no human evidence base for those claims; marketing that mentions them is reaching past what the studies show.

What to actually take

The one practical decision that matters more than the dose is the purity of the product. Palmitoleic acid (the omega-7) differs from palmitic acid (the common saturated fat in palm oil) by exactly one chemical bond. Cheaper or crude products can contain enough residual palmitic acid to offset the lipid benefit you came for. The well-studied Provinal ingredient was specifically engineered to strip it out; sea buckthorn oils have a naturally less favourable ratio. Reading the label for total palmitoleate content — and for the absence of palmitic acid — is the difference between reproducing the trial and not.

Where this goes wrong

Underdosed product. A cheap "omega-7" capsule may deliver 30 mg of palmitoleate, not 200. The Bernstein effects don't reproduce at a fraction of the trial dose.
The wrong sea buckthorn oil. Seed oil instead of pulp oil means you're getting an omega-6 / omega-3 mix and almost no omega-7.
Expecting fish-oil-tier effects. Omega-3 has dozens of large trials and a Cochrane-level evidence base. Omega-7 has one good sixty-person trial. The size of the evidence base, and the size of the realistic expected effect, are different by an order of magnitude.
Skipping the follow-up labs. The point of an evidence-thin intervention with measurable endpoints is that you can actually measure them. Bloodwork at baseline and again at eight-to-twelve weeks tells you whether you're a responder. Without that, you're paying for a guess.

When to be cautious

The safety profile in the published trials was unremarkable — no serious adverse events at studied doses, and a long food-use history with sea buckthorn. A few practical cautions are still worth naming.

What else you could do for the same goal

For the lipid case, the much stronger evidence sits with prescription icosapent ethyl (a purified EPA, 4 g/day) in statin-treated patients with high triglycerides — the REDUCE-IT trial showed about a 25% drop in cardiovascular events, a hard outcome no fatty-acid supplement currently matches. Standard EPA/DHA fish oil at 2–4 g/day has roughly comparable triglyceride effects to omega-7 with a much larger evidence base. Statins, niacin, and bempedoic acid are the pharmacologic options if LDL is the target.

For dry eye, the foundational interventions are warm compresses and lid hygiene, with cyclosporine drops and punctal plugs as escalation. Omega-7 is a reasonable adjunct, not a primary treatment — and not a replacement for an actual eye exam if the dryness is severe.

The buying picture

Purified palmitoleate runs about $20–35 a month at the studied dose. Sea buckthorn oil capsules are a few dollars cheaper, with the trade-off that palmitoleate content varies between brands and is sometimes not even on the label. Both are widely available online and from larger supplement retailers; pharmacies tend not to stock them. One soft-gel a day with food is the entire protocol — no titration, no cycling, no preparation. It is, by supplement standards, one of the easier things to add to a daily routine.

Related entries to look at next

If the omega-7 case feels thin, the larger and better-studied omega-3 (EPA/DHA) literature is the natural next stop — most of the same goals (lipids, inflammation, dry eye) have stronger evidence over there. For high triglycerides specifically, icosapent ethyl has hard-outcome trial data that no over-the-counter fatty-acid supplement currently matches. If dry eye is the real problem driving the interest, a dedicated dry-eye management entry covers the full first-line picture — lid hygiene, omega-3, prescription drops — that omega-7 should slot into rather than replace.

Substance + claimed effects

Palmitoleic acid (C16:1n-7, cis-9-hexadecenoic acid) is a monounsaturated omega-7 fatty acid. It is endogenously produced in the liver and adipose by stearoyl-CoA desaturase-1 (SCD1) from the saturated palmitic acid, and is also obtained from a handful of food sources concentrated in it: sea buckthorn berry (pulp) oil (~30–40% of total fatty acids), macadamia nut oil (~17–22%), and, in the trans isomer (trans-palmitoleate, C16:1n-7t), ruminant dairy fat (~0.2–0.5% of milk fat). As a supplement it is sold in two main forms: purified concentrated palmitoleic acid from algal or fish-derived triglycerides (the branded Provinal ingredient and equivalents, typically 200–220 mg palmitoleate per soft-gel) and sea buckthorn oil capsules (variable palmitoleate content, often 100–300 mg per 1 g capsule). The supplement is marketed as an omega-7, distinct from omega-3 and omega-6.

Claims fall into four clusters: (1) lipid and inflammation — lower LDL, lower triglycerides, higher HDL, lower hs-CRP; (2) insulin sensitivity and metabolic health — improved glucose handling, reduced hepatic fat, lower incident type-2 diabetes; (3) skin and mucous-membrane support — relief of dry eye, dry skin, atopic dermatitis, post-menopausal vaginal dryness; (4) cardiovascular endpoints by extension from lipid changes. This entry covers all four holistically. The "lipokine" framing — that palmitoleate is a hormone-like fatty-acid signal from adipose tissue that improves systemic metabolism (Cao et al. 2008) — is the unifying mechanism story.

Evidence by addressing question

mechanism

Science. Palmitoleate was named a lipokine in a 2008 Cell paper from the Hotamisligil lab (Cao et al. 2008). Mice lacking adipose-tissue fatty-acid-binding proteins had elevated circulating palmitoleate and were protected against insulin resistance and hepatic steatosis; infusing palmitoleate into wild-type mice reproduced the protection, increasing insulin-stimulated glucose disposal in skeletal muscle and suppressing diacylglycerol accumulation and SREBP-1c-driven lipogenesis in the liver. This established a model in which adipose-derived palmitoleate acts as an endocrine signal — distinct from the bulk-fuel role of most fatty acids.

Mechanism. Several pathways have been mapped downstream:

PPAR-α activation in liver, increasing fatty-acid oxidation and suppressing SREBP-1c-driven de novo lipogenesis — the lipid-lowering arm (Frigolet & Gutiérrez-Aguilar 2017).
GLUT4 translocation in muscle, enhancing insulin-stimulated glucose uptake (Cao et al. 2008).
NF-κB suppression in adipose macrophages and hepatocytes, lowering TNF-α and IL-6 output — the inflammation arm; this is the proposed pathway for the hs-CRP drop seen in human trials (de Souza et al. 2018).
GPR120/FFAR4 ligand activity, the same receptor that mediates omega-3 anti-inflammatory effects, though palmitoleate is a weaker ligand than EPA/DHA (de Souza et al. 2018).
Hepatic SCD1 feedback: exogenous palmitoleate suppresses hepatic SCD1 expression, which may explain why supplementation does not simply add to endogenous synthesis (Frigolet & Gutiérrez-Aguilar 2017).

A related lipid class, palmitic-acid hydroxy-stearic acids (PAHSAs), was identified in 2014 as an endogenous anti-diabetic and anti-inflammatory family produced from palmitoleate-related pathways (Yore et al. 2014). PAHSAs are not the same molecule as palmitoleate, but the lineage strengthens the case that 16-carbon monounsaturates serve signaling roles.

Source matters. A subtle and load-bearing point: endogenous palmitoleate (made by hepatic SCD1 from carbohydrate-driven de novo lipogenesis) tracks poorly with metabolic health — elevated hepatic-fraction palmitoleate is a marker of fatty liver and insulin resistance in some human studies. Exogenous palmitoleate (from diet or supplement) appears to act differently, both because it bypasses the SCD1 pathway and because its tissue distribution differs (more adipose, less hepatic). This source-asymmetry is the central confound in interpreting circulating-palmitoleate observational data (Frigolet & Gutiérrez-Aguilar 2017).

evidence

Science — human RCT. The single best-quality human trial of supplemental purified palmitoleate is Bernstein et al. 2014, a double-blinded, randomised, placebo-controlled study in 60 hyperlipidemic adults given 220 mg/day of purified palmitoleate (the Provinal formulation, ~90% palmitoleate, derived from fish triglycerides) for 30 days (Bernstein et al. 2014). Versus placebo, the treatment arm showed hs-CRP reduced by ~44% (p<0.001), triglycerides reduced by ~15% (p<0.05), LDL reduced by ~8% (p<0.05), and HDL increased by ~5% (p<0.05). Effect sizes are modest but coherent, and the hs-CRP drop is large enough to flag. The trial was 30 days only, single-centre, and industry-adjacent (sponsored by Tersus Pharmaceuticals, the Provinal manufacturer); independent replication is sparse.

Science — supportive smaller trials. Yagi et al. 2017 gave 280 mg/day purified palmitoleate to Japanese adults with metabolic syndrome for 12 weeks and reported similar directional improvements in HOMA-IR and lipid panel, though the effect sizes were smaller than Bernstein's, and the sample (n≈40) was modest (Yagi et al. 2017). No large multi-site RCT has yet been done.

Science — observational data, cis vs trans. The most-cited "omega-7 lowers diabetes risk" data point is the Cardiovascular Health Study cohort analysis: circulating trans-palmitoleate (a dairy-fat biomarker) was associated with a ~60% lower incidence of type-2 diabetes over 3 years in the highest vs lowest quintile (Mozaffarian et al. 2010). The Multi-Ethnic Study of Atherosclerosis (MESA) replicated the inverse association in a larger, more diverse cohort (~3,700 adults), with a ~50% lower diabetes incidence in the highest quintile (Mozaffarian et al. 2013). Crucially: this is the trans isomer, found in dairy and from gut-microbial biohydrogenation in ruminants. Supplemental palmitoleate is the cis isomer. The two molecules have different receptor affinities and tissue handling; assuming the cis-supplement reproduces the trans-isomer epidemiology is the most common error in popular omega-7 marketing.

For the cis isomer, observational data are mixed. Stefan et al. 2010 found circulating cis-palmitoleate independently and positively predicted insulin sensitivity in 100 non-diabetic adults — consistent with the lipokine model (Stefan et al. 2010). Other groups have found the opposite: high hepatic-fraction palmitoleate correlated with fatty liver and metabolic dysfunction, attributed to de novo lipogenesis as the source (the SCD1-paradox; see mechanism). The cis-isomer evidence cuts both ways, and the cut tracks source rather than the molecule itself (Frigolet & Gutiérrez-Aguilar 2017).

Science — dry eye. Larmo et al. 2010 randomised 86 individuals with dry eye to 2 g/day sea buckthorn oil (delivering ~30% palmitoleate) or placebo for 3 months: the active arm showed attenuated rise in tear-film osmolarity (an objective dry-eye biomarker) and improvement in reported dryness and redness symptoms (Larmo et al. 2010). The design is strong (RCT, double-blind, validated endpoints); the sample is moderate.

Science — skin / mucosa. Yang et al. 1999 randomised 49 atopic dermatitis patients to 4 weeks of sea buckthorn seed oil (rich in linoleic and α-linolenic), pulp oil (rich in palmitoleic), or paraffin placebo; the pulp-oil arm showed improvement in clinical atopic dermatitis severity scores, though the trial was small and not multi-site (Yang et al. 1999). Larmo et al. 2014 randomised 116 post-menopausal women with vaginal atrophy to 3 g/day sea buckthorn oil or placebo for 3 months, finding improvement in vaginal epithelium integrity scores (Larmo et al. 2014).

Science — macadamia / dietary route. Trials of whole macadamia nuts (40–90 g/day, 4–5 weeks, hyperlipidemic men) reduced total cholesterol ~5%, LDL ~6%, and modestly raised HDL (Garg et al. 2003; Garland et al. 2008). These confound palmitoleate's contribution with macadamia's other monounsaturates (oleic acid is the dominant fatty acid), phytosterols, and fibre — the effect can't be cleanly attributed to omega-7.

Mechanism. Mouse data are consistent and dose-dependent: chronic palmitoleate administration (300 mg/kg/day, ~10× a human supplement dose by body mass) reduces insulin resistance and hepatic lipid accumulation in genetic-diabetic KK-Ay mice (Yang ZH et al. 2011). Animal effect sizes are larger than human-trial effect sizes — the typical translational gap.

Community / lay evidence. Provinal-style omega-7 supplements have a moderate-sized r/Supplements and Reddit footprint, with a few hundred user posts: typical reports describe improvements in skin moisture and dry-eye symptoms within 2–6 weeks at 210–420 mg/day, occasional reports of improved lipid panels at follow-up bloodwork. Negative reports are mostly "I felt nothing" rather than adverse effects. Volume is small compared to omega-3 (orders of magnitude smaller user base); the consistency of the dry-eye signal is moderate.

Practice / clinical consensus. No major guideline body (AHA, AACE, ESC, ADA) recommends palmitoleate supplementation. Lipidologists are aware of Bernstein 2014 but treat the result as preliminary; cardiology consensus remains EPA/DHA for the omega-fatty-acid niche, with the IPE/icosapent ethyl pathway dominating prescription guidance after the REDUCE-IT trial. Functional and integrative medicine practitioners more commonly recommend omega-7, often paired with omega-3, particularly for dry-eye and mild dyslipidemia. Ophthalmology has not formally endorsed sea buckthorn oil for dry eye, though it appears in some practitioner-level recommendation lists for mild evaporative dry eye.

protocol

Science. Bernstein 2014 used 220 mg/day purified palmitoleate (Provinal, >90% palmitoleate, with stearic and palmitic acids removed) for 30 days; Yagi 2017 used 280 mg/day for 12 weeks (Bernstein et al. 2014; Yagi et al. 2017). Sea buckthorn oil trials used 2–3 g/day of total oil, delivering roughly 200–600 mg palmitoleate depending on whether the oil is from pulp (high) or seed (low) (Larmo et al. 2010; Larmo et al. 2014).

Practice. Common supplement-industry guidance is 210–420 mg/day purified palmitoleate, or 1–3 g/day sea buckthorn oil. Onset for the dry-eye and skin effects is reported within 2–6 weeks; lipid changes typically appear by 4–8 weeks. Taken with food to aid lipid-soluble absorption. Stacking with omega-3 is common practice and not contraindicated.

Crucial purity point. Palmitoleate is structurally close to palmitic acid (saturated, atherogenic) — they differ only by one double bond. Crude or poorly-purified omega-7 products can contain substantial residual palmitic acid, which would offset or reverse the lipid benefit. The Bernstein trial used a product specifically engineered to remove palmitic and stearic acids; sea buckthorn oils naturally have a less favourable cis-palmitoleate-to-palmitate ratio. This is the central practical-purchase decision.

contraindications

Science. No serious adverse events were reported in Bernstein 2014, Yagi 2017, or the Larmo sea buckthorn trials. The trials excluded pregnant/breastfeeding women and those on antithrombotic medications; the safety data for these groups is absent rather than negative.

Mechanism / practice. Theoretical concerns: like fish-oil-derived omega-3, fish-derived palmitoleate may have a mild antiplatelet effect at higher doses, suggesting caution combined with warfarin or DOACs. No clinically meaningful interaction has been documented at supplement doses (de Souza et al. 2018). Sea buckthorn oil is generally regarded as safe, with a long history of food use in Russia, Mongolia, and Northern Europe.

misconceptions

The trans-isomer transfer error. The most prevalent marketing claim — "omega-7 lowers your diabetes risk by 60%" — derives from the Mozaffarian 2010 Cardiovascular Health Study finding for trans-palmitoleate, a dairy-fat biomarker (Mozaffarian et al. 2010). Supplemental omega-7 is the cis isomer, structurally distinct (the double bond is in the trans rather than cis configuration), with different receptor affinities. The observational association may not transfer to supplements — and even if it did, "60% lower" is a relative risk in the highest quintile of circulating biomarker, not an absolute treatment effect.

"Omega-7 is just another omega." The omega-3 / omega-6 / omega-7 numbering refers to where the first double bond sits counting from the methyl end of the carbon chain. Omega-3 and omega-7 have entirely different metabolic roles: omega-3 (EPA, DHA, ALA) is polyunsaturated and the primary substrate for resolvins and protectins; omega-7 is monounsaturated and acts predominantly as a lipokine signal and structural lipid. Substituting one for the other does not make sense biochemically.

"All sea buckthorn oils are equivalent." Pulp oil is rich in palmitoleate (~30–40%); seed oil is rich in linoleic and α-linolenic acid (palmitoleate ~1–3%). Many supplement labels say "sea buckthorn oil" without specifying — the palmitoleate dose can vary 10-fold.

"Endogenous production means supplementation is unnecessary." Endogenous (hepatic SCD1-driven) palmitoleate is associated with worse metabolic health in some human cohorts because its production tracks carb overconsumption; exogenous (dietary or supplement) palmitoleate appears to act differently and suppresses SCD1 — the two pools are not interchangeable for the lipokine signaling role (Frigolet & Gutiérrez-Aguilar 2017).

audience

Most plausible responders (per the evidence base):

Hyperlipidemic adults with elevated hs-CRP — Bernstein 2014's actual study population, where the strongest effects were seen.
Dry-eye sufferers, especially evaporative / meibomian-gland-dysfunction phenotype — Larmo 2010 evidence base, postmenopausal women particularly well-represented.
Atopic dermatitis or chronic dry-skin patients — modest evidence (Yang 1999); often a low-cost addition to a topical regimen.
Post-menopausal women with vaginal dryness — Larmo 2014 evidence, modest effect.
Mild metabolic syndrome — biologically plausible but evidence base is one small trial (Yagi 2017).

Less plausible: anyone seeking "cognitive" or "energy" benefits — no human evidence base. People on prescription lipid therapy or icosapent ethyl: incremental benefit unstudied.

alternatives

For lipid + hs-CRP: prescription icosapent ethyl (EPA, 4 g/day) has REDUCE-IT trial data showing 25% cardiovascular-event reduction in statin-treated patients with high triglycerides — an order of magnitude more evidence than omega-7. Standard EPA/DHA fish oil at 2–4 g/day has comparable triglyceride effects to omega-7's modest signal. Niacin and bempedoic acid are pharmacologic options.

For dry eye: omega-3 supplementation (DREAM trial showed no clear benefit at the population level, but the trial's design has been critiqued); lid hygiene; warm compresses; cyclosporine eye drops; punctal plugs.

For dry skin / atopic dermatitis: topical emollients (the first-line intervention), topical steroids for flares, dupilumab for moderate-severe disease. Oral evening primrose oil has a similarly modest evidence base for atopic dermatitis (the GLA pathway).

failure-modes

Wrong product. Cheap "omega-7" products are often crude sea buckthorn seed oil, delivering 10–50 mg palmitoleate per capsule when the studied doses are 210–280 mg. A user taking three capsules a day of such a product is unlikely to reproduce the trial effects.

Palmitate contamination. If the product is poorly purified, residual saturated palmitic acid can offset the lipid benefit (palmitate is mildly atherogenic at supraphysiologic doses).

Confounding the dry-eye signal. Sea buckthorn oil contains carotenoids, vitamin E, and other minor components; isolating the palmitoleate contribution requires the purified form, which has not been studied for dry eye.

Expecting omega-3-tier effects. Omega-3 has dozens of large RCTs; omega-7 has one ~60-person trial. Users who expect comparable effect sizes will be disappointed.

Stopping at one month. The lipid and CRP effects in Bernstein 2014 appeared at 30 days, but no longer-term human data exists. Users may discontinue without re-checking labs.

practicalities

Cost: purified palmitoleate (Provinal-based products) is roughly $20–35/month at the studied dose of ~210 mg/day. Sea buckthorn oil capsules are roughly $15–25/month at 1–2 g/day, with variable palmitoleate content. Yearly cost: ~$200–400.

Availability: widely sold online (Amazon, iHerb, Vitacost) and in larger supplement retailers (GNC). Less commonly stocked in pharmacies. Branded ingredients to look for: Provinal (the purified-fish-derived ingredient used in most trial-grade products), or sea buckthorn pulp oil (specifically pulp, not seed).

Form: soft-gel capsule, taken with food. Once-daily dosing is fine; no need to split.

history

Sea buckthorn (Hippophaë rhamnoides) has a long folk-medicine history in Tibetan, Mongolian, and Russian traditions, used for skin, digestion, and wound healing. Soviet space and military programmes commissioned research on it starting in the 1950s. The modern Western interest in palmitoleate-as-supplement traces to the Cao et al. 2008 lipokine paper, which framed palmitoleate as a signalling molecule rather than a structural lipid, and the subsequent commercialisation of Provinal in the early 2010s.

stakes

Modest. Skipping omega-7 supplementation does not produce a felt deficit; this is not a deficiency state. The most concrete consequence of skipping is forgoing a small, evidence-thin chance of modest lipid and inflammation improvements, and (for the relevant subgroups) a real but small chance of dry-eye or mucous-membrane symptom relief.

payoff

For the right user (dry-eye, mild dyslipidemia, atopic dermatitis), the realistic payoff is a small but real improvement in the specific symptom: less gritty eyes, smaller blood-test movement on next labs, slightly more comfortable skin. Not transformative; defensible as a low-cost adjunct.

out-of-scope

Adjacent topics worth their own treatment: omega-3 / EPA / DHA supplementation (the larger, better-evidenced sibling); icosapent ethyl prescription pathway; dry-eye comprehensive management; sea buckthorn topical applications (separate substance — topical use is a different bioavailability question).

The credibility range

The optimist case

Palmitoleate is a genuine lipokine — the Cao 2008 Cell paper, replicated in multiple mouse models, established a mechanistically coherent endocrine signalling role distinct from bulk-fuel fatty acids (Cao et al. 2008; Frigolet & Gutiérrez-Aguilar 2017). The Bernstein 2014 RCT delivered a clean, large hs-CRP reduction (~44%) plus directionally consistent lipid improvements in 30 days at a modest dose (Bernstein et al. 2014), and Yagi 2017 reproduced the directional signal in a different population (Yagi et al. 2017). Two large observational cohorts (CHS and MESA) link the related trans-palmitoleate to a 50–60% lower diabetes incidence (Mozaffarian et al. 2010; Mozaffarian et al. 2013). Stefan 2010 showed circulating cis-palmitoleate independently predicts insulin sensitivity in non-diabetic humans (Stefan et al. 2010). Larmo 2010 delivered a well-designed RCT showing real dry-eye benefit (Larmo et al. 2010). The discovery of PAHSAs (Yore et al. 2014) suggests the 16-carbon monounsaturate family has multiple downstream lipid-signalling roles still being mapped. Safety profile is clean; cost is low. This is a credible, modestly-positive intervention for the right user.

The skeptic case

The human RCT evidence base is one ~60-person single-centre industry-sponsored trial (Bernstein 2014) plus one smaller Japanese trial (Yagi 2017). No independent replication; no multi-site Phase III. Effect sizes are modest; lipid changes (LDL −8%, TG −15%, HDL +5%) are smaller than statins or even niacin and the hs-CRP drop has not been independently confirmed. The most-cited "60% lower diabetes risk" data is for trans-palmitoleate (Mozaffarian 2010, 2013), a different molecule, and even there the association is observational and probably confounded by other dairy components — the more nuanced read is that trans-palmitoleate is a marker of low-fat-restriction dietary patterns, not a causal agent. Endogenously made cis-palmitoleate is associated with worse metabolic profiles in some cohorts (the SCD1 paradox), undermining a clean "palmitoleate good" story. Animal evidence is large but uses pharmacologic doses 10× supplement doses. Mucous-membrane / skin trials are small (Larmo 2010 n=86, Yang 1999 n=49); the dry-eye field broadly is plagued by placebo response and inconsistent endpoints. No major clinical guideline endorses palmitoleate supplementation. The supplement industry has a clear incentive to extrapolate dairy-biomarker epidemiology to capsules. The strongest skeptic position: this is a plausible-mechanism, weak-evidence intervention being sold against the optics of stronger but irrelevant observational data.

The author's call

Lands centre-skeptic on the metabolic claims, centre-optimist on the dry-eye claim. Bernstein 2014 is a real and clean trial — credit where due — but its findings need independent multi-site replication before warranting more than "worth trying if you have the indication." The trans-isomer epidemiology is not transferable evidence for supplements. The dry-eye / mucous-membrane signal is small but consistent across trials and mechanistically anchored (palmitoleate is a structural component of meibomian-gland and sebaceous-gland lipids), and the cost-to-benefit is favourable at supplement doses. Overall: a modest entry, honestly positioned as "small but real for specific uses, oversold for the metabolic uses, do not expect omega-3-tier effects." Score reflects this — useful, but not in the catalogue's top tier.

Stakeholder + incentive map

Commercial: Tersus Pharmaceuticals (Provinal manufacturer, branded ingredient sold to many supplement labels); sea buckthorn agricultural industry (Russia, China, Mongolia produce the bulk of global supply); macadamia industry (Australia, Hawaii) — though macadamia oil is largely a culinary rather than supplement market.
Professional: Functional and integrative medicine practitioners (more receptive to omega-7); conventional cardiology and endocrinology guideline bodies (silent — no endorsement, no condemnation).
Counter-incentive: Competing omega-3 industry (much larger; omega-3 marketing has historically positioned palmitoleate as the "less effective" cousin). Statin and lipid-lowering pharmacy.
Research: Hotamisligil lab at Harvard (the lipokine framework's intellectual home); Larmo / Kallio group in Finland (the sea buckthorn evidence base); smaller Japanese groups working on metabolic-syndrome populations.

Population variability

Hyperlipidemic adults with baseline hs-CRP > 2 mg/L — the Bernstein 2014 study population. Best evidence for response.
Post-menopausal women — strongest dry-eye and vaginal-mucosa evidence (Larmo trials), as estrogen withdrawal compromises mucous-membrane lipid quality.
Adults with evaporative dry-eye phenotype (lipid-layer deficiency, often meibomian gland dysfunction) — mechanism predicts response.
Atopic-dermatitis adults — small-trial evidence; the linoleic / α-linolenic component of sea buckthorn seed oil may matter as much as the palmitoleate.
Healthy normolipidemic adults — no clear evidence of benefit; the lipid and CRP machinery has no abnormal substrate to act on.
Lean insulin-sensitive adults — palmitoleate's metabolic effects scale with baseline dysfunction; no benefit expected at baseline normal.
People with high de novo lipogenesis (excess carb intake, fatty liver) — already have elevated endogenous palmitoleate without the metabolic benefit; supplementation effects in this population are unstudied and may be different.

Knowledge gaps

What hasn't been studied: independent multi-site replication of the Bernstein 2014 RCT; long-term (>6 months) human data on lipid, glycaemic, or cardiovascular endpoints; randomised comparison of purified palmitoleate vs sea buckthorn oil; head-to-head with EPA/DHA on lipid panel; effect on hard cardiovascular outcomes (MI, stroke, cardiovascular mortality); dose-response curve in humans (most trials cluster around 210–280 mg/day, no formal titration study); interaction with statin therapy; mechanism by which exogenous palmitoleate behaves differently from endogenous in tissue.

What would change the call: a 1,000+ participant multi-site RCT with the same lipid and CRP endpoints would either confirm Bernstein 2014 (moving evidence to 3–4) or fail to reproduce it (moving evidence to 1). Hard-outcome trial data (CVOT) would be required to put omega-7 anywhere near the icosapent-ethyl tier. A direct comparison of cis vs trans isomer in humans would resolve the most prominent marketing-vs-science gap.

Scope vs brief. The brief named lipids, insulin sensitivity, skin, and mucous-membrane health. All four are covered: lipids and inflammation through the Bernstein 2014 RCT in the evidence section; insulin sensitivity through the lipokine mechanism and the cis/trans confound; skin and mucous-membrane through Larmo 2010 (dry eye), Yang 1999 (atopic dermatitis), and Larmo 2014 (vaginal atrophy) in evidence and audience. None of the four was silently dropped.

No dream narrative. Overall score ~10; well below the obligatory 40 threshold. The honest hook for this entry is the clarity / debunking lever (the trans-isomer transfer error is the single most useful thing a reader can take away), which doesn't naturally support an aspirational projection. Wrote dek and tagline straight per spec.

Rating calls worth flagging.

evidence: 2 over 3 — one good single-centre industry-sponsored RCT plus one underpowered confirmation is the textbook definition of "sparse but mechanism-plausible." A 3 would require independent multi-site replication that doesn't yet exist.
applicability: 2 over 3 — defensible to go either way. Dry-eye prevalence alone is ~15–30% of adults; mild dyslipidemia is ~40%. But the evidence is weak enough that claiming broad addressable audience felt overreach. Honest restraint.
controversy: 2 not 3 — mainstream cardiology is silent, not opposed. The cis/trans confusion and SCD1-source paradox are genuine scientific disagreements but at the margins, not a paradigm fight.
health_short_term: 2 over 3 — Bernstein's hs-CRP drop (~44%) flirts with 3 territory, but the effect base is one ~60-person trial. Not yet a "clear functional improvement" tier in the population sense.

Contraindications field left empty. The closed vocabulary (pregnancy, breastfeeding, blood-thinners, etc.) doesn't quite match — there's no documented contraindication at supplement doses, only the theoretical mild-antiplatelet caution that's covered in the warning callout. Adding blood-thinners would overstate; leaving empty matches the safety data.

Future-link candidates (write or wire when they exist).

Omega-3 (EPA/DHA) — the larger, better-evidenced sibling. Cross-link is natural; pointed at it in alternatives and out-of-scope.
Icosapent ethyl (Vascepa) — the prescription pathway with REDUCE-IT outcome data. Likely warrants its own entry.
Dry-eye management — first-line interventions (lid hygiene, warm compresses, prescription drops) that omega-7 should slot into.
Statin therapy / lipid management — the conventional lipid story this entry sits beside.

Separate-entry candidates.

Sea buckthorn topical applications — different bioavailability profile and different evidence base from oral supplementation; folds out as a skin-category entry rather than under this one.
Trans-palmitoleate as a dairy-fat biomarker — relevant to the broader full-fat-dairy vs low-fat-dairy debate but distinct from the supplement; better placed under a dairy or saturated-fat entry.

Hard call: framing the trans-isomer issue without losing the casual reader. The cis/trans distinction is the single most important thing for a buyer to understand and the easiest to lose them on. Resolved by mentioning it in the dek as "a chemically different version of the molecule found in dairy fat" (no chemistry jargon), then unpacking it more fully in evidence and misconceptions. The word "isomer" never appears in reader prose.